

Zoom WEBINAR



DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHIES: NOW & NEXT

An initiative of



Wednesday, November 20th

- 7:30 pm CET
- 5:30 am (+1 day) Melbourne
- 9:30 pm Nairobi
- 3:30 pm Buenos Aires
- 12:30 pm Chicago
- 10:30 am San Francisco

Simultaneous translation will be available in French, Italian, Spanish.



To Register scan the QR code
or visit
https://bit.ly/DEE_Webinar

This event has been made possible thanks to a sponsorship grant from Jazz Pharmaceuticals.



Jazz Pharmaceuticals®

Presentation 1: Personalised Epilepsy Management: What does it mean for people with DEEs?

Speaker: Prof. Patrick Kwan, Professor, Department of Neuroscience, Monash Institute of Medical Engineering, VIC - Australia.

- What is personalised epilepsy management?
- What role does medical artificial intelligence play in personalised treatment selection and discovery?
- What role do human stem cells play in personalised treatment selection and discovery?
- What does the future hold and how should we prepare to advocate for access to innovation?

Reflection: Dr Tracy Dixon-Salazar, PhD, Executive Director, LGS Foundation, USA.

Presentation 2: Gene Therapy for DEEs: Today and Tomorrow

Speaker: Dr Gaia Colasante, PhD, Project Leader, IRCCS Ospedale San Raffaele, Milan, Italy.

- What is gene therapy? How does it work?
- Where are we now? Examples from DS, LGS and TSC.
- What's happening at the bench, and what's in the pipeline? (incl. experimental models).
- What do we know about secondary responses? What other challenges and opportunities are there?
- What does the future hold and how should we prepare to advocate for access to innovation?

Reflection: Dr Pooja Takhar, Joint CEO, The Tuberous Sclerosis Association, UK

Presentation 3: Exploration of Innovations beyond Drug Treatments

Speaker: Dr Mark Cook, Chair of Medicine at St. Vincent's Hospital, VIC - Australia.

- What role do medical devices play in the ongoing management of DEEs?
- How do you assess the real efficacy of medical devices?
- What other innovations should be considered for management of DEEs?
- What does the future hold and how should we prepare to advocate for access to innovation?

Reflection: Simona Borroni, President, Dravet Syndrome European Federation